{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:03:46Z","timestamp":1697630626923},"reference-count":53,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.vaccine.2010.08.107","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T08:42:32Z","timestamp":1285058552000},"page":"7529-7535","source":"Crossref","is-referenced-by-count":6,"title":["Distinct immune responses of recombinant plasmid DNA replicon vaccines expressing two types of antigens with or without signal sequences"],"prefix":"10.1016","volume":"28","author":[{"given":"Yun-Zhou","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2010.08.107_bib0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.molmed.2006.03.007","article-title":"Gene-based vaccines: recent technical and clinical advances","volume":"12","author":"Ulmer","year":"2006","journal-title":"Trends Mol Med"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.107_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11259-008-9040-3","article-title":"DNA vaccines and their applications in veterinary practice: current perspectives","volume":"32","author":"Dhama","year":"2008","journal-title":"Vet Res Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2010.08.107_bib0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/14760584.7.2.175","article-title":"Current progress of DNA vaccine studies in humans","volume":"7","author":"Lu","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"10.1016\/j.vaccine.2010.08.107_bib0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/hum.2006.17.1051","article-title":"DNA vaccines: recent developments and future possibilities","volume":"17","author":"Liu","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.107_bib0025","first-page":"522","article-title":"Preclinical safety and biodistribution of sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen","volume":"19","author":"Ramirez","year":"2008","journal-title":"Hum Gene"},{"issue":"6","key":"10.1016\/j.vaccine.2010.08.107_bib0030","first-page":"510","article-title":"Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization","volume":"1","author":"Driver","year":"1998","journal-title":"Curr Res Mol Ther"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2010.08.107_bib0035","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0264-410X(99)00271-6","article-title":"DNA and RNA-based vaccines: principles, progress and prospects","volume":"18","author":"Leitner","year":"1999","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2010.08.107_bib0040","doi-asserted-by":"crossref","first-page":"13412","DOI":"10.1128\/JVI.01799-07","article-title":"Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine","volume":"81","author":"Ljungberg","year":"2007","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.08.107_bib0045","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nbt0698-562","article-title":"Enhancing immune responses using suicidal DNA vaccines","volume":"16","author":"Berglund","year":"1998","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.107_bib0050","first-page":"51","article-title":"Enhancement of tumor-specific immune response with plasmid DNA replicon vectors","volume":"60","author":"Leitner","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.107_bib0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/IAI.71.1.575-579.2003","article-title":"Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A","volume":"71","author":"Kirman","year":"2003","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2010.08.107_bib0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1099\/vir.0.80481-0","article-title":"Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1","volume":"86","author":"Nordstrom","year":"2005","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.107_bib0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm813","article-title":"Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways","volume":"9","author":"Leitner","year":"2003","journal-title":"Nat Med"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2010.08.107_bib0070","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.vaccine.2003.10.013","article-title":"Apoptosis is essential for the increased efficacy of alphavirus-based DNA vaccines","volume":"20","author":"Leitner","year":"2004","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2010.08.107_bib0075","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1016\/j.vaccine.2006.04.059","article-title":"Type I Interferons are essential for the efficacy of replicase-based DNA vaccines","volume":"24","author":"Leitner","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2010.08.107_bib0080","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/gt.2008.164","article-title":"Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines","volume":"16","author":"Diebold","year":"2009","journal-title":"Gene Ther"},{"issue":"52","key":"10.1016\/j.vaccine.2010.08.107_bib0085","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1016\/j.vaccine.2007.10.016","article-title":"Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A","volume":"25","author":"Yu","year":"2007","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2010.08.107_bib0090","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1016\/j.vaccine.2009.08.022","article-title":"Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.107_bib0095","first-page":"124","article-title":"Expression of the Hc fargment of Clostridium botulinum neurotoxin serotype A in mammalian cells using recombinant Semliki Forest Virus expression system","volume":"24","author":"Yu","year":"2008","journal-title":"Chin J Biotech"},{"issue":"6","key":"10.1016\/j.vaccine.2010.08.107_bib0100","first-page":"521","article-title":"Expression of domain 4 of the protective antigen from anthrax in mammalian cells using recombinant semliki forest virus replicon vectors","volume":"30","author":"Yu","year":"2006","journal-title":"Bull Acad Mil Med Sci"},{"issue":"21","key":"10.1016\/j.vaccine.2010.08.107_bib0105","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2009.02.091","article-title":"The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2010.08.107_bib0110","first-page":"389","article-title":"Soluble expression of domain 4 of the protective antigen of anthrax toxin in E. coli","volume":"16","author":"Yu","year":"2005","journal-title":"Lett Biotechnol"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2010.08.107_bib0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-2478(97)00171-5","article-title":"Differential induction of immunoglobulin G subclasses by immunization with DNA vectors containing or lacking a signal sequence","volume":"61","author":"Haddad","year":"1998","journal-title":"Immunol Lett"},{"issue":"12","key":"10.1016\/j.vaccine.2010.08.107_bib0120","doi-asserted-by":"crossref","first-page":"10214","DOI":"10.1128\/JVI.73.12.10214-10223.1999","article-title":"Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response","volume":"73","author":"Lewis","year":"1999","journal-title":"J Virol"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2010.08.107_bib0125","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1016\/S0264-410X(99)00171-1","article-title":"Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines","volume":"17","author":"Rice","year":"1999","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2010.08.107_bib0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-1759(99)00086-1","article-title":"Enhancement of antibody responses by DNA immunization using expression vectors mediating efficient antigen secretion","volume":"228","author":"Svanholm","year":"1999","journal-title":"J Immuno Method"},{"issue":"6","key":"10.1016\/j.vaccine.2010.08.107_bib0135","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1128\/IAI.68.6.3097-3102.2000","article-title":"DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.DNA vaccine","volume":"68","author":"Delogu","year":"2000","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.107_bib0140","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.70.1.292-302.2002","article-title":"DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis","volume":"70","author":"Delogu","year":"2002","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.107_bib0145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0042-6822(03)00417-3","article-title":"Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES","volume":"314","author":"Kim","year":"2003","journal-title":"Virology"},{"issue":"45","key":"10.1016\/j.vaccine.2010.08.107_bib0150","first-page":"5252","volume":"23","author":"Liang","year":"2005","journal-title":"Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses"},{"issue":"2","key":"10.1016\/j.vaccine.2010.08.107_bib0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.virol.2006.08.052","article-title":"DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice","volume":"358","author":"Costa","year":"2007","journal-title":"Virology"},{"issue":"5102","key":"10.1016\/j.vaccine.2010.08.107_bib0160","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2010.08.107_bib0165","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1016\/j.vaccine.2008.04.017","article-title":"Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies","volume":"26","author":"Golden","year":"2008","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2010.08.107_bib0170","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.vaccine.2009.01.128","article-title":"Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge","volume":"27","author":"Kaur","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2010.08.107_bib0175","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1128\/JVI.71.7.5528-5539.1997","article-title":"Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes","volume":"71","author":"Hinkula","year":"1997","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2010.08.107_bib0180","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0264-410X(99)00253-4","article-title":"Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A","volume":"18","author":"Clayton","year":"2000","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.107_bib0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02255918","article-title":"DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice","volume":"7","author":"Shyu","year":"2000","journal-title":"J Biomed Sci"},{"issue":"23","key":"10.1016\/j.vaccine.2010.08.107_bib0190","first-page":"3110","volume":"21","author":"Bennett","year":"2003","journal-title":"DNA vaccination protects against botulinum neurotoxin type F. vaccine"},{"issue":"29\u201330","key":"10.1016\/j.vaccine.2010.08.107_bib0195","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1016\/j.vaccine.2004.04.006","article-title":"Efficacy DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters","volume":"22","author":"Jathoul","year":"2004","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2010.08.107_bib0200","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0264-410X(98)00210-2","article-title":"Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen","volume":"17","author":"Gu","year":"1999","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.vaccine.2010.08.107_bib0205","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1016\/j.vaccine.2008.03.064","article-title":"Potentiation of an anthrax DNA vaccine with electroporation","volume":"26","author":"Luxembourg","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2010.08.107_bib0210","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/IAI.67.4.1860-1865.1999","article-title":"Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin","volume":"67","author":"Varughese","year":"1999","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2010.08.107_bib0215","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/IAI.70.3.1653-1656.2002","article-title":"A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection","volume":"70","author":"Flick-Smith","year":"2002","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.107_bib0220","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/IAI.01722-07","article-title":"Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant","volume":"76","author":"Park","year":"2008","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.107_bib0225","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.vaccine.2007.11.072","article-title":"Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses","volume":"26","author":"Zhang","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.107_bib0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/eji.200838058","article-title":"Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses","volume":"39","author":"Midha","year":"2009","journal-title":"Eur J Immunol"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2010.08.107_bib0235","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2010.08.107_bib0240","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jviromet.2008.08.011","article-title":"Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice","volume":"154","author":"Luo","year":"2008","journal-title":"J Virol Method"},{"issue":"42","key":"10.1016\/j.vaccine.2010.08.107_bib0245","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1016\/j.vaccine.2009.07.033","article-title":"Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation","volume":"27","author":"Seo","year":"2009","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2010.08.107_bib0250","doi-asserted-by":"crossref","first-page":"13601","DOI":"10.1073\/pnas.0405557101","article-title":"A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores","volume":"101","author":"Hermanson","year":"2004","journal-title":"PNAS"},{"issue":"9","key":"10.1016\/j.vaccine.2010.08.107_bib0255","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/IAI.69.9.5709-5715.2001","article-title":"Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system","volume":"69","author":"Lee","year":"2001","journal-title":"Infect Immun"},{"issue":"47\u201348","key":"10.1016\/j.vaccine.2010.08.107_bib0260","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1016\/j.vaccine.2006.06.004","article-title":"Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice","volume":"24","author":"Lee","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2010.08.107_bib0265","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/IAI.71.3.1491-1496.2003","article-title":"Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge","volume":"71","author":"Lee","year":"2003","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10013265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10013265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:27:53Z","timestamp":1591921673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10013265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":53,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0264410X10013265"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.08.107","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}